Table 1.
Ongoing sarcoma immunotherapy clinical trials
| Paradigm | Intervention | Disease | Status | Clinical trial ID | Locations |
| Adoptive cell transfer | TIL IL-2 Fludarabine Cyclophosphamide |
High grade STS | Phase I, Recruiting | NCT04052334 | USA |
| NY-ESO-1c259T cells | Myxoid/round cell liposarcoma | Phase II, Recruiting | NCT02992743 | USA | |
| Engineered NY-ESO-1 (GSK3377794) T cells Fludarabine Cyclophosphamide |
Synovial Sarcoma | Phase II, Recruiting | NCT03967223 | USA | |
| ADP-A2M4 SPEAR anti-MAGE-A4 T cells | Synovial Sarcoma, Myxoid/round cell liposarcoma |
Phase II, Recruiting | NCT04044768 | USA | |
| CAR T cells | Anti-GD2 (C7R-GD2.CAR) T cells Fludarabine Cyclophosphamide |
Relapsed OS, relapsed Ewing’s sarcoma, relapsed RMS | Phase I, Recruiting | NCT03635632 | USA |
| Autologous anti-HER-2 CAR T Fludarabine Cyclophosphamide |
STS | Phase I, Active | NCT00902044 | USA | |
| Vaccines | Tumor lysate loaded DC Vaccine Gemcitabine Imiquimod |
STS, Bone sarcoma | Phase I, Active | NCT01803152 | USA |
| GVAX | Clear Cell Sarcoma, Alveolar Soft Part sarcoma |
Phase I, Active | NCT00258687 | USA | |
| MVA expressing p53 | STS | Phase I, Active | NCT02432963 | USA | |
| Adoptive NK cell therapy | NK cell infusion HSCT | RMS | Phase I, II, Completed | NCT01386619 | Germany Switzerland |
| NK cell infusion and recombinant IL-15 | Sarcoma | Phase I, Completed |
NCT01875601 | USA | |
| Expanded, activated NK cells | Ewing Sarcoma, RMS | Phase I, II, Recruiting | NCT02409576 | Singapore | |
| NK cell infusion HSCT | Ewing Sarcoma, OS, RMS, STS | Phase II, Active, not recruiting | NCT01807468 | South Korea |
CAR, chimeric antigen receptor; DC, dendritic cell; GD2, disialoganglioside; HSCT, hematopoietic stem cell transplantion; IL-15, interleukin 15; MVA, modified vaccinia Ankara; OS, osteosarcoma; RMS, rhabdomyosarcoma; STS, soft-tissue sarcoma; TIL, tumor infiltrating lymphocyte.